Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Join | Sign in
Home>Resources>Webcasts>This Webcast
  Webcasts

Identifying miRNA in Biofluids to be Applied as Robust Biomarkers for Disease, Toxicology or Injury Studies – The case of Minimally Invasive Colorectal Cancer Detection

Peter Mouritzen, Exiqon, speaking at Genomics Research Europe 2012
Date Posted: Thursday, January 24, 2013
Access to this article and other content is for registered users.

Join the Technology Networks Community

  • Access to the latest scientific news, products and research through Technology Networks
  • Upload and share your posters on ePosters
  • View a library of 1,800+ scientific and medical posters
  • A library of 3,000+ scientific videos on LabTube


Sign In



Forgotten your details? Click Here
If you already have an account with Technology Networks, please use your existing login details. If you do not yet have an account please join here.

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Related Content

Exiqon Licenses Biomarkers From Aarhus University Hospital
Exiqon A/S has exclusively licensed prostate cancer biomarkers discovered and validated by Aarhus University Hospital, Department of Molecular Medicine (MOMA).
Wednesday, December 03, 2014
Redefining High Risk Patients With Stage II Colon Cancer
microRNA-21 identified as an independent prognostic biomarker.
Friday, September 12, 2014
Exiqon Licenses Locked Nucleic Acids for Infectious Disease Diagnostics to BD
BD will use Exiqon's proprietary LNA™ technology in defined products for infectious disease diagnostics.
Wednesday, June 23, 2010
Exiqon and MultiD Sign Development and Distribution Agreement for microRNA qPCR Analysis Solution
Agreement incorporates a specifically adapted version of the GenEx qPCR analysis software for Exiqon's new microRNA qPCR platform.
Wednesday, May 26, 2010
Exiqon Appoints President and General Manager of new US Operations
Michael Kallelis will have the overall responsibility for launching and operating Exiqon’s US office to be located in the Boston area.
Friday, January 06, 2006
Exiqon Wins Ernst & Young Entrepeneur of the Year Award
Exiqon selected as winner in the BIOTECH 2005 category.
Tuesday, November 22, 2005
Exiqon A/S appoints permanent CEO

Monday, February 24, 2003
Scientific News
NIH-funded Study Points Way Forward for Retinal Disease Gene Therapy
Benefits for Leber congenital amaurosis peak after one to three years, then diminish.
Study Points to Possible Treatment for Lethal Pediatric Brain Cancer
NIH-funded preclinical study suggests epigenetic drugs may be used to treat leading cause of pediatric brain cancer death.
Mutations in Two Genes Linked to Familial Pulmonary Fibrosis and Telomere Shortening
PARN and RTEL1 genes strengthen the link between lung fibrosis and telomere dysfunction.
Proteomics Identifies DNA Repair Toolbox
Max-Planck scientists identify protein profiles of DNA repair.
Diet Swap has Dramatic Effects on Colon Cancer Risk for Americans and Africans
New study confirms that a high fibre diet can substantially reduce risk.
Statement on NIH Funding of Research Using Gene-Editing Technologies in Human Embryos
Researchers modify the gene responsible for a potentially fatal blood disorder using CRISPR/Cas9 technology.
Scientists Identify Key Receptors Behind Development of AML
Blocking ITIM-receptor signaling in combination with conventional therapies may represent a novel strategy for AML treatment.
Id1 Gene Interferes With Immune System
Uncovering new functions of a gene implicated in cancer growth opens new therapeutic possibilities.
Bumblebee Genome Mapped
A research collaboration spearheaded by ETH Zurich has shed light on the genome of two commercially important species of bumblebees. The findings provide unexpected insights into the ecology and evolution of bumblebees and honeybees.
Gene Variants Show Potential In Predicting Rheumatoid Arthritis Disease Outcomes
Arthritis Research UK-funded scientists at The University of Manchester have identified a new way in which genotyping can be used to predict disease outcomes among sufferers of rheumatoid arthritis.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters